Dasvir
Generic Name
Daclatasvir
Manufacturer
Popular Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| dasvir 60 mg tablet | ৳ 400.00 | N/A |
Description
Overview of the medicine
Dasvir (Daclatasvir) is an antiviral medication used in combination with other drugs to treat chronic Hepatitis C virus (HCV) infection in adults. It works by targeting specific proteins of the virus to prevent its replication.
Uses & Indications
Dosage
Adults
60 mg orally once daily, in combination with Sofosbuvir or other appropriate antiviral agents, for 12-24 weeks depending on genotype and patient history.
Elderly
No specific dose adjustment required for elderly patients.
Renal_impairment
No dose adjustment required for mild, moderate, or severe renal impairment, or for patients on dialysis.
How to Take
Take orally once daily, with or without food. Swallow the tablet whole; do not chew, crush, or break it.
Mechanism of Action
Daclatasvir is a direct-acting antiviral agent that targets the Hepatitis C virus NS5A protein. By binding to NS5A, it inhibits viral RNA replication and virion assembly, thereby stopping the spread of the virus.
Pharmacokinetics
Onset
Viral load reduction can be observed within days of starting treatment.
Excretion
Excreted primarily in feces (approximately 80%), with a smaller portion excreted in urine (approximately 6.4%).
Half life
Approximately 12-15 hours.
Absorption
Rapidly absorbed, with peak plasma concentrations (Cmax) achieved within 1-2 hours after oral administration. Bioavailability is approximately 67%.
Metabolism
Primarily metabolized by cytochrome P450 3A (CYP3A) enzyme.
Side Effects
Contraindications
- •Hypersensitivity to Daclatasvir or any component of the formulation.
- •Co-administration with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine, St. John's wort) due to potential loss of therapeutic effect.
Drug Interactions
0
Strong CYP3A inducers (e.g., rifampin, phenytoin): Reduce Daclatasvir levels, avoid co-administration.
1
Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin): Increase Daclatasvir levels, may require dose adjustment.
2
Amiodarone (with Sofosbuvir): Risk of severe bradycardia, avoid co-administration.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.
Overdose
In cases of overdose, there is no specific antidote. Treatment should consist of general supportive measures, including monitoring of vital signs and observation of the patient's clinical status. Hemodialysis does not effectively remove Daclatasvir.
Pregnancy & Lactation
Category B (for Daclatasvir alone). No adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult a doctor. It is unknown if Daclatasvir is excreted in human milk; caution is advised during breastfeeding.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from manufacturing date.
Availability
Pharmacies nationwide
Approval Status
Approved by DGDA
Patent Status
Patent expired in many countries, generic versions available
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
